Optinose launch of Xhance could far exceed expectations, says Jefferies
After surveying 50 high prescribing physicians, Jefferies analyst David Steinberg says Optinose's launch of Xhance could far exceed expectations. Physicians report 57% of their patients will receive prescriptions annually at peak, Steinberg tells investors in a research note. Using the most conservative response regarding patient use per year, implied peak sales could reach $1.1B, well above the $700M consensus, the analyst contends. He believes that while payer pushback is inevitable, the survey suggests Xhance "could be one of the top sector launches in some time." The anlayst keeps a Buy rating on Optinose shares with a $31 price target.